HOLOS biomarkers, based on chromosomal conformation signatures, are an integral component in the development of preventative personalised healthcare, performance optimisation and multi-faceted wellness outcomes.

PROJECT 1: Epigenetic Response to Exercise in Humans

• This discovery project was undertaken in conjunction with Federation University in Ballarat, Australia. It was designed to identify epigenetic markers with predictive value for endurance or strength based training

• 17 epigenetic markers were identified with strong predictive capabilities. These 17 markers are now being taken through to a validation study

• A further 36 epigenetic markers were identified as having strong relevance to the predictive model

• The successful conclusion of the discovery project confirms the ability of EpiSwitch™ to identify epigenetic biomarkers in healthy human subjects with a new patent now filed to protect the marker discovery process

Commercial application

Our exercise focused on epigenetic markers will deliver two commercially available tests; epigenetically derived exercise type confirmation and epigenetically measured response to exercise. 

These will have commercial value to:

• Consumer genetic testing companies

• Sports and fitness groups

• Professional sports organisations

• Insurance companies

• Population health organisations and government health initiatives

• HOLOS blood tests are complementary in nature to the current testing regime of any of these groups

Our tests provide the following benefits:

• Deeper end-user engagement opportunities

• Ability to develop a recurring revenue model

• Increased adherence due to early indication of desired outcomes

• Improved exercise efficiency and outcomes as a result of determining the most beneficial type of exercise to be undertaken

• An accurate measure of the impact of exercise on key biological indicators such as immune response pathways and inflammation markers